Recently by Christopher C. Loeber
Pharmaceuticals
As Opioid Suits Loom, Now’s the Time to Act on D&O Insurance
Coverage for opioid exposures remains relatively untested, with existing case law increasing the uncertainty.
Litigation related to to the opioid crisis is on the rise, and now corporate shareholders are entering the fray. In recent months, shareholders have brought a number of lawsuits...
Read More